| scholarly article | Q13442814 |
| P50 | author | Andreas Laupacis | Q110344826 |
| Peter Austin | Q37384108 | ||
| Paula Rochon | Q42384149 | ||
| Muhammad M Mamdani | Q88325570 | ||
| Gary Naglie | Q88866631 | ||
| P2093 | author name string | David N Juurlink | |
| Geoffrey M Anderson | |||
| Alex Kopp | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| naproxen | Q1215575 | ||
| acute myocardial infarction | Q18558122 | ||
| P304 | page(s) | 481-486 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly | |
| P478 | volume | 163 |
| Q95359642 | Q95359642 |
| Q34603772 | A population-based study of the drug interaction between proton pump inhibitors and clopidogrel |
| Q28211367 | A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution |
| Q24793068 | Acute coronary disease Athero-Inflammation: Therapeutic approach |
| Q79273482 | Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk |
| Q39565271 | Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population |
| Q37310162 | Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study |
| Q28218005 | An economic model of long-term use of celecoxib in patients with osteoarthritis |
| Q35758411 | An evidence-based update on nonsteroidal anti-inflammatory drugs |
| Q36025935 | Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2. |
| Q37044230 | Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? |
| Q28167045 | Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis |
| Q46704739 | Bleeding complications in patients on celecoxib and warfarin |
| Q40722594 | CNODES: the Canadian Network for Observational Drug Effect Studies |
| Q34282832 | COX-2 and beyond: Approaches to prostaglandin inhibition in human disease |
| Q38941017 | Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks |
| Q28191924 | Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance |
| Q35777371 | Cardiovascular effects of selective cyclooxygenase-2 inhibitors |
| Q36761358 | Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs |
| Q44960512 | Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications |
| Q36439704 | Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? |
| Q36520638 | Cardiovascular risks of cyclooxygenase inhibition |
| Q36299969 | Celecoxib and cardiovascular risks |
| Q37257008 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study |
| Q34584630 | Celecoxib: a review of its use in the management of arthritis and acute pain |
| Q46882737 | Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making |
| Q55387053 | Characterizing the Use of Telepsychiatry for Patients with Opioid Use Disorder and Cooccurring Mental Health Disorders in Ontario, Canada. |
| Q36349740 | Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs |
| Q37947341 | Comparative risks of non-prescription analgesics: a structured topic review and research priorities. |
| Q44975072 | Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia |
| Q24282604 | Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies |
| Q28211435 | Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial |
| Q93050783 | Concurrent psychiatry for patients enrolled in opioid agonist treatment: a propensity score matched cohort study in Ontario Canada |
| Q36486905 | Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs |
| Q28181807 | Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction |
| Q40430509 | Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries? |
| Q34323910 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study |
| Q28212127 | Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? |
| Q28219220 | Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk |
| Q35827780 | Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships |
| Q46743815 | Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease |
| Q38833741 | Developing anti-inflammatory therapeutics for patients with osteoarthritis. |
| Q33723762 | Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases |
| Q33941101 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study |
| Q41511728 | Discrepancy among observational studies: example of naproxen-associated adverse events |
| Q79165284 | Do selective cyclo-oxygenase-2 nonsteroidal anti-inflammatory agents increase the risk for acute myocardial infarction? |
| Q35772541 | Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology |
| Q36304331 | Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now? |
| Q36238800 | Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada |
| Q90448405 | Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study |
| Q57295112 | Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease |
| Q46450711 | Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q28174778 | Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin |
| Q46456979 | Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme |
| Q28218432 | Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs |
| Q28171150 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model |
| Q28196511 | Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? |
| Q36141793 | Life after Vioxx: the clinical implications |
| Q45928209 | Macrolide-induced digoxin toxicity: a population-based study. |
| Q36404975 | Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? |
| Q34589334 | Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis. |
| Q38101544 | Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies |
| Q26784322 | NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species |
| Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
| Q28196509 | Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction |
| Q36869571 | Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe? |
| Q43678694 | On the selective inhibitors of Cyclooxygenase-2: do we have a last word? |
| Q37964882 | Paradigm shift in the pharmacological management of periodontal diseases |
| Q52349399 | Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview. |
| Q37337118 | Potential prescription patterns and errors in elderly adult patients attending public primary health care centers in Mexico City |
| Q36693881 | Practical application of nonrandomized research to patient care: a case study of nesiritide |
| Q37014117 | Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages |
| Q35636594 | Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs |
| Q36586263 | Rates of hemorrhage during warfarin therapy for atrial fibrillation |
| Q25257303 | Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors |
| Q30437125 | Relative thromboembolic risks associated with COX-2 inhibitors |
| Q36309261 | Resolution of inflammation in periodontitis |
| Q80577019 | Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract |
| Q28551188 | Risk of Bias in Systematic Reviews of Non-Randomized Studies of Adverse Cardiovascular Effects of Thiazolidinediones and Cyclooxygenase-2 Inhibitors: Application of a New Cochrane Risk of Bias Tool |
| Q45260921 | Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study |
| Q30234512 | Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data |
| Q28200524 | Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis |
| Q54920356 | Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. |
| Q45175627 | Risk of cardiovascular events and rofecoxib: cumulative meta-analysis |
| Q24555478 | Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis |
| Q34148370 | Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evi |
| Q36600810 | Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. |
| Q44996394 | Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study |
| Q36173750 | Selective COX-2 inhibitors and risk of myocardial infarction |
| Q36645806 | Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? |
| Q28212914 | Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity |
| Q33634928 | Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study |
| Q64243457 | Social licence and the general public's attitudes toward research based on linked administrative health data: a qualitative study |
| Q44627113 | Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk |
| Q40377176 | The cardiovascular safety of celecoxib |
| Q34636574 | The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame |
| Q37267020 | The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. |
| Q42578372 | Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors |
| Q44905269 | Treatment of osteoarthritis of the knee joint. Efficacy and tolerance to acemetacin slow release in comparison to celecoxib |
| Q35496564 | Trends in opioid use and dosing among socio-economically disadvantaged patients. |
| Q36598115 | Use of non-aspirin nonsteroidal antiinflammatory drugs and the risk of cardiovascular events |
| Q33906348 | Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community |
| Q38409156 | Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. |
| Q59216355 | What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs |
| Q94601377 | [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?] |
| Q82930983 | [NSAIDs and COX-2-inhibitors: current status] |
| Q94601375 | [What do we know about the cardiovascular toxicity of the NSAIDs?] |
Search more.